Oral delayed-release mesalazine: A review of its use in ulcerative colitis and Crohn's disease

Drugs

Volumn 57, Issue 3, 1999, Pages 383-408

  Prakash, Amitabh ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; CORTICOSTEROID; CYTOKINE; EUDRAGIT; FAMOTIDINE; FREE RADICAL; ICOSANOID; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ALLERGIC DISEASE; BLOOD TOXICITY; CLINICAL TRIAL; CROHN DISEASE; DELAYED RELEASE FORMULATION; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DYSPEPSIA; ENTERIC COATED TABLET; FAINTNESS; HEADACHE; HEPATITIS; HUMAN; KIDNEY DISEASE; LUNG DISEASE; LUPUS ERYTHEMATOSUS; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PANCREATITIS; POSTOPERATIVE PERIOD; RASH; RECTAL DRUG ADMINISTRATION; REMISSION; REVIEW; RHINITIS; ULCERATIVE COLITIS; VERTIGO;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; COLITIS, ULCERATIVE; CROHN DISEASE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EICOSANOIDS; HUMANS; MESALAMINE; RANDOMIZED CONTROLLED TRIALS; TISSUE DISTRIBUTION;

EID: 0033021470     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957030-00013     Document Type: Review

References (94)

1. Riley SA. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis ? Gut 1998; 42: 761-3
2. Geier DL, Miner Jr PB. New therapeutic agents in the treatment of inflammatory bowel disease. Am J Med 1992 Aug; 93: 199-208
3. Järnerot G. New salicylates as maintenance treatment in ulcer-alive colitis. Gut 1994 Sep; 35: 1155-8
4. Lauritsen K, Laursen LS, Rask-Madsen J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II). Clin Pharmacokinet 1990 Aug; 19: 94-125
5. Osterwald HP. Pharmaceutic development: mesalazine. Scand J Gastroenterol 1990; 25 Suppl. 172: 43-6
6. Gionchetti P, Campieri M, Venturi A, et al. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. Aliment Pharmacol Ther 1996; 10: 601-5
7. Rijk MCM, Van Schaik A, Van Tongeren JHM. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scand J Gastroenterol 1992 Oct; 27: 863-8
8. Christensen LA, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-amino-salicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990 Oct; 4: 523-33
9. Forbes A, Chadwick C. Mesalazine preparations [letter]. Lancet 1997 Nov 1; 350: 1329
10. Botoman VA, Bonner GF, Botoman DA. Management of inflammatory bowel disease. Am Fam Physician 1995; 57: 57-68
11. Rhodes J, Thomas G, Evans BK. Inflammatory bowel disease management: some thoughts on future drug developments. Drugs 1997 Feb; 53: 189-94
12. Travis SPL, Jewell DP. Salicylates for ulcerative colitis: their mode of action. Pharmacol Ther 1994; 63: 135-61
13. Greenfield SM, Punchard NA, Teare JP, et al. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993 Aug; 7: 369-83
14. Harting JW. New developments in the pharmacotherapy of inflammatory bowel disease. Pharm Weekbl Sci 1992 Aug; 14: 275-86
15. 4 in isolated colonic mucosal cells. Curr Med Res Opin 1996; 13: 417-25
16. Eliakim R, Karmeli F, Chorev M, et al. Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis. Scand J Gastroenterol 1992 Nov; 27: 968-72
17. Fox C, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicyclic acid. Dig Dis Sci 1991 Feb; 36: 179-84
18. Horn H, Preelik G, Stange EF, et al. Modulation of arachidonic acid metabolism by olsalazine and other aminosalicylates in leukocytes. Scand J Gastroenterol 1991 Aug; 26: 867-79
19. Crotty B, Hoang P, Dalton HR, et al. Salicylates used in inflammatory bowel disease and colchicine impair interferon-γ induced HLA-DR expression. Gut 1992 Jan; 33: 59-64
20. Di Paolo MC, Merrelt MN, Crotty B, et al. 5-Aminosalicylic acid inhibits the impaired epithelial harrier function induced by gamma interferon. Gut 1996 Jan; 38: 115-9
21. Crotty B, Rosenberg WMC, Aronson JK, et al. Inhibition of binding of interferon-γ to its receptor by salicylates used in inflammatory bowel disease. Gut 1992 Oct; 33: 1353-7
22. Mahida YR, Lamming CED, Gallagher A, et al. 5-Aminosalicylic acid is a potent inhibitor of interleukin 1β production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991 Jan; 32: 50-4
23. Gertner DJ, Rampton DS, de Nucci G, et al. Eicosanoid release by rectal mucosa in vitro in ulcerative colitis: effects of conventional and potential new therapies. Eur J Gastroenterol Hepatol 1992 Oct; 4: 837-41
24. Rachmilewitz D, Karmeli F, Schwartz LW, et al. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut 1992 Jul; 33: 929-32
25. Bruin KF, Hommes DW, Jansen J, et al. Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 1995 Aug; 7: 791-5
26. Stevens C, Lipman M, Fabry S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995 Jan; 272: 399-406
27. Mazlam MZ, Montazeri G, Hodgson HJF. The effects of some anti-inflammatory agents on cytokine release from human monocytes in vitro. Eur J Gastroenterol Hepatol 1993 Jul; 5: 515-20
28. Gionchetti P, Guarnieri C, Campieri M, et al. Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci 1991 Feb; 36: 174-8
29. Greenfield SM, Punchard NA, Thompson RPH. Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicyclic acid. Gut 1991 Oct; 32: 1156-9
30. Dallegri F, Ottonello L, Ballestero A, et al. Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. Gut 1990 Feb; 31: 184-6
31. Sandoval M, Liu X, Mannick EE, et al. Peroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamine. Gastroenterology 1997 Nov; 113: 1480-8
32. Laursen LS, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990 Nov; 31: 1271-6
33. Raimundo AH, Evans DF, Rogers J, et al. Colonic pH in ulcerative colitis: relevance to mezalazine therapy [abstract no. 4001. Am J Gastroenterol 1993 Sep; 88: 1581
34. De Vos M, Verdievel H, Schoonjans R, et al. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 1992 Oct; 33: 1338-42
35. Hussain F, Ajjan R, Trudgill N, et al. Dose loading with oral mesalazine-optimising drug concentrations in the mucosa [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A928
36. Hussain F, Ajjan R, Trudgill N, et al. Single and divided dose delayed-release mesalazine: are traditional dosing regime in IBD outmoded? [abstract]. Gastroenterology 1996 Apr: 110 Suppl.: A928
37. Bossi A, Gionchetti P, Campieri M, et al. Comparative pharmacokinetic study of two multiple and single unit controlled release oral dosage forms of 5-ASA [abstract]. Ital J Gastroenterol 1991 Dec; 23: 641
38. Corey AE, Rose GM, Conklin JD. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine. J Int Med Res 1990 Nov-Dec; 18: 441-53
39. Hussain F, Ajjan R, Weir N, et al. Mesalazine release from coated tablets: effect of drugs which alter gastrointestinal PH [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A928
40. Wiltink EHH, Mulder CJJ, Stolk LML, et al. Absorption of oral mesalazine-containing preparations and the influence of famotidine on the absorption. Scand J Gastroenterol 1990; 25: 579-84
41. Riley SA, Tavares TA, Bishai PM, et al. Mesalazine release from coated tablets: effect of dietary fibre. Br J Clin Pharmacol 1991 Aug; 32: 248-50
42. Tzivras M, Konstandinidis A, Hatzis G, et al. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. Eur J Gastroenterol Hepatol 1997 Jul; 9: 729-30
43. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 1997 Feb; 92: 204-11
44. Levine DS, Pruitt R, Riff D, et al. A multi-center, double-blind dose-response trial of Colazide® (balsalazide disodium) and Asacol® (mesalamine) for mild-moderately active ulcerative colitis. Gastroenterology 1997 Apr; 112 Suppl.: A 1026
45. Green JRB, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitits. Gastroenterology 1998 Jan; 114: 15-22
46. Miglioli M, Bianchi Porro G, Brunetti G, et al. Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. Eur J Gastroenterol Hepatol 1990 Jun; 2: 229-34
47. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mild to moderately active ulcerative colitis: a randomized study. N Engl J Med 1987; 317: 1625-9
48. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicenter study. Ann Intern Med 1991 Sep; 115: 350-5
49. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997 Oct; 92: 1867-71
50. Cobden I, Al-Mardini H, Zaitoun A, et al. Is topical therapy necessary in acute distal colitis? Double-blind comparison of high-dose oral mesalazine versus steroid enemas in the treatment of active distal ulcerative colitis. Aliment Pharmacol Ther 1991 Oct; 5: 513-22
51. Green JRB, Gibson JA, Kerr GD, et al. Maintenance treatment with balsalazide provides more effective control of nocturnal symptoms of ulcerative colitis (UC) than delayed-release mesalazine [abstract no. TW167]. Gut 1998 Mar; 42 Suppl. 1: A42
52. d'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997 Jul; 92: 1143-7
53. Courtney MG, Nunes DP, Bergin CF, et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992 May; 339: 1279-81
54. Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomised, placebo-controlled trial. Ann Intern Med 1996 Jan; 124: 204-11
55. Desideri S, Ardizzone S, Petrillo M, et al. Two different oral formulations of 5-amino-salicylic acid (5-ASA) in maintenance treatment of ulcerative colitis [abstract]. Ital J Gastroenterol 1991 Dec; 23: 643
56. Dew MJ, Hughes P, Harries AD, et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. BMJ 1982; 285: 1012
57. Dew MJ, Harries AD, Evans N, et al. Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth. BMJ 1983; 287: 23-4
58. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988 Jun; 94: 1383-9
59. Nakshabendi IM, Duncan A, Russell RI. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis? Postgrad Med J 1992 Mar; 68: 189-91
60. Abenhaim L, Sutherland LR, Field LG, et al. Has the introduction of a new mesalamine containing compound altered the clinical course of ulcerative colitis patients? [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A850
61. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996 Mar; 334: 841-8
62. Tremaine WJ, Schroeder KW, Harrison JM, et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation. Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994 Dec; 19: 278-82
63. Prantera C, Pallone F, Brunetti G, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992; 103: 363-8
64. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Aliment Pharmacol Ther 1994 Feb; 8: 35-43
65. Faber SM, Korelitz BI. Experience with eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease: an open study. J Clin Gastroenterol 1993 Oct; 17: 213-8
66. Donald IP, Wilkinson SP. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine. Postgrad Med J 1985; 61: 1047-8
67. Barletti C, Sambataro A, Barbaro S, et al. Outcomes from a large clinical survey in 302 patients suffering from Crohn's disease, treated with oral mesalazine (Asacol Rm) [abstract]. Ital J Gastroenterol 1991; 23: 647-8
68. Pruitt RE, Gremillion D, Herring R, et al. Safety and tolerance of oral 5-ASA (Asacol®) in the treatment of ulcerative colitis and Crohn's disease: results of the US multicenter open-label study [abstract]. Gastroenterology 1991; 100 (5) Suppl. Pt 2: A241
69. Hanauer S, Regalli G, Verst-Brasch C. Safety of long-term mesalamine in patients with inflammatory bowel disease [abstract no. 343]. Am J Gastroenterol 1996 Sep; 91: 1971
70. Schroeder KW, Tremaine WJ, Albrecht HH, et al. Safety of long-term mesalamine therapy in patients with inflammatory bowel disease [abstractl. Gastroenterology 1996 Apr; 110 Suppl.: A 1011
71. Smith Kline & French Laboratories. Asacol® Data Sheet. Welwyn Garden City, Hertfordshire, England, 1997
72. D'Agata ID, Vanounou T, Seidman EG, Mesalamine in pediatric inflammatory bowel disease: a 10 year experience [abstract]. Gastroenterology 1995 Apr; 108 Suppl.: A805
73. Pardi DS, Tremaine WJ, Sandborn WJ, et al. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998; 93: 504-14
74. Schreiber S, Hämling J, Zehnter E, et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997; 40: 761-6
75. Stretch GL, Campbell BJ, Dwarakanath AD, et al. 5-Amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Aliment Pharmacol Ther 1996 Dec; 10: 941-7
76. Hanauer SB, Verst-Brasch C, Regalli G. Renal safety of long-term mesalamine therapy in inflammatory bowel disease (IBD) [abstract]. Gastroenterology 1997 Apr; 112 Suppl.: A991
77. Mani V. Mesalazine-associated interstitial nephritis [letter]. Nephrol Dial Transplant 1997 Mar; 12: 622
78. World MJ, Stevens PE, Ashton MA, et al. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996 Apr; 11: 614-21
79. Popoola J, Muller AF, Pollock L, et al. Late onset interstitial nephritis associated with mesalazine treatment. BMJ 1998 Sep; 317: 795-7
80. Brouillard M, Gheerbrant JD, Gheysens Y, et al. Interstitial nephritis and mesalazine: three new cases [in French]. Gastroenterol Clin Biol 1998 Aug-Sep; 22: 724-6
81. World MJ. Mesalazine-associated interstitial nephritis: reply [letter]. Nephrol Dial Transplant 1997 Mar; 12: 623
82. Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther 1992 Feb; 6: 51-9
83. Dew MJ, Harries AD, Evans BK, et al. Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine. Lancet 1983; 11: 801
84. Mulder CJJ, van den Hazel SJ. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. Medial Inflamm 1998; 7: 135-6
85. Ardizzone S, Molteni P, Bollani S, et al. Guidelines for the treatment of ulcerative colitis in remission. Eur J Gastroenterol Hepatol 1997 Sep; 9: 836-41
86. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993 Apr; 118: 540-9
87. British National Formulary. Mesalazine. Vol. 36. London: The Pharmaceutical Press. 1998 Sep
88. Murthy S, Flanigan A. Recent developments in inflammatory bowel disease therapy. Expert Opin Ther Pat 1997 Jul; 7:695-715
89. Gibson PR. Inflammatory bowel disease: current concepts in pathogenesis and therapy. Clin Immunother 1994 Aug; 2: 134-60
90. Ardizzone S, Bianchi Porro G. A practical guide to the management of distal ulcerative colitis. Drugs 1998 Apr; 55: 519-42
91. de Franchis R, Vecchi M, Carpinelli L, et al. Comparison of the efficacy and safety of sulphasalazine and mesalazines in the maintenance treatment of ulcerative colitis: a meta-analysis. Eur J Gastroenterol Hepatol 1993 Jul; 5: 505-10
92. Travis SPL, Tysk C, de Silva HJ, et al. Optimum dosage of olsalazine for maintaining remission in ulcerative colitis. Gut 1994; 35: 1282-6
93. Fockens P, Mulder CJJ, Tytgat GNJ, et al. Comparison of the efficacy and safety of 1.5 compared with 3.0g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol 1995 Nov; 7: 1025-30
94. Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113: 1465-73